Bioatla, Inc. · NASDAQ:BCAB
Bioatla — AACR 2020 Virtual Annual Meeting II
14 slides from Bioatla's conference presentation, February 2023
Slide 1: Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors
Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors Ana Paula G Cugnetti, PhD BioAtla LLC, San Diego, CA
Slide 2: Disclosure Information
Disclosure Information • AACR 2020 Virtual Annual Meeting II Speaker: Ana Paula G Cugnetti, PhD I have the following financial relationships to disclose: Consultant for: N/A Speaker’s Bureau for: N/A Grant/Research support from: BioAtla, LLC Stockholder in: BioAtla, LLC Honoraria from: N/A Employee
Slide 3: Conditionally Active Biologics (CAB) Bispecific Platform
Conditionally Active Biologics (CAB) Bispecific Platform DO NOT POST
Slide 4: CAB Technology Leverages Differential pH of Cancer Cells
CAB Technology Leverages Differential pH of Cancer Cells CABs designed to be active only under certain conditions found in disease tissue o Ability to generate antibodies that are only active in the Tumor Microenvironment (TME) • Increased safety • Higher potency o Warburg Effect • Cancer cells have
Slide 5: CABs Bind Selectively and Reversibly Based on the Cellular Microenvironment
CABs Bind Selectively and Reversibly Based on the Cellular Microenvironment DO NOT POST
Slide 6: CAB Bispecific Antibody Activates T cells in the Tumor Microenvironment Minimizing Toxicity
CAB Bispecific Antibody Activates T cells in the Tumor Microenvironment Minimizing Toxicity while Maintaining Potency • T cells are physically linked to tumor cells via Bispecific mAbs composed of a T cell-binding domain and a tumor-binding domain • Bispecific mAbs activate T cells through binding o
Slide 7: CAB T Cell Engagers Family for Rapid Generation and Maximum Therapeutic Index
CAB T Cell Engagers Family for Rapid Generation and Maximum Therapeutic Index DO NOT POST
Slide 8: EpCAM (Epithelial Cell Adhesion Molecule)
EpCAM (Epithelial Cell Adhesion Molecule) ➢ Highly expressed on adenocarcinomas • Lung, colon, Ovarian, Prostate, Breast. ➢ Epithelial cell proliferation is driven through EpCAM signal transduction ➢ Expressed in virtually all epithelia containing tissues ➢ Loss of function in normal tissues causes
Slide 9: EpCAM x CD3 Mono and Dual CAB Bispecific mAbs MiXeno HCT116 Xenograft Studies
EpCAM x CD3 Mono and Dual CAB Bispecific mAbs MiXeno HCT116 Xenograft Studies DO NOT POST
Slide 10: Lower Inflammatory Response in Non-Human Primates Treated with Mono CAB WT-EpCAM x CAB-CD3
Lower Inflammatory Response is Observed in Non-Human Primates Treated with Mono CAB WT-EpCAM x CAB-CD3
Slide 11: Immuno-oncology B7 Family Member- B7-H3
Immuno-oncology B7 Family Member- B7-H3
Slide 12: Summary of CAB CD3 Bispecific Antibodies
Summary of CAB CD3 Bispecific Antibodies ➢ Mouse tumor xenograft efficacy data demonstrated that WT and CAB CD3 bispecific antibodies which target WT EpCAM have equivalent efficacy (nominal value = 1). ➢ NHP administered with single doses of either WT-EpCAM x CAB-CD3 or WT-EpCAM x WT-CD3: • CAB-CD3
Slide 13: Summary
Summary ➢ CAB Technology platform allows the generation of biologics with conditional and reversible binding activity. ➢ Broadly applicable to antibody formats including ADCs, bispecifics, CAR-Ts and other therapeutic proteins. ➢ CABs are active in the tumor microenvironment, but not under physiolog
Slide 14: Acknowledgement
Acknowledgement BioAtla’s Team members Haizhen Liu Jing Wang Charles Xing Christina Wheeler Mathew Lucas Cathy Chang Gerhard Frey Bill Boyle Jay Short